The recent entry of an activist investor draws attention to the potential for Bio-Rad's shares to be re-rated. Read more on ...

Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.

Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the ...

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -5.14% in ...

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) stands ...

Detailed price information for Bio-Rad Laboratories (BIO-N) from The Globe and Mail including charting and trades.

Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP) ...